Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction

ST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute myocardial infarction (AMI). We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI)...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European heart journal Ročník 26; číslo 7; s. 667
Hlavní autoři:	Sorajja, Paul, Gersh, Bernard J, Costantini, Costantino, McLaughlin, Michael G, Zimetbaum, Peter, Cox, David A, Garcia, Eulogio, Tcheng, James E, Mehran, Roxana, Lansky, Alexandra J, Kandzari, David E, Grines, Cindy L, Stone, Gregg W
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.04.2005
Témata:	Aged Angioplasty, Balloon, Coronary - methods Coronary Circulation - physiology Electrocardiography Female Humans Male Microcirculation - physiology Middle Aged Multivariate Analysis Myocardial Infarction - physiopathology Myocardial Infarction - therapy Myocardial Reperfusion - methods Prognosis Recurrence Survival Analysis Treatment Outcome
ISSN:	0195-668X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	ST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute myocardial infarction (AMI). We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI) in AMI has greater prognostic utility than either measure alone. The 30 days and 1 year clinical outcomes of 456 patients were assessed as a function of SigmaSTR and MB after primary PCI from the CADILLAC trial. SigmaSTR and MB were concordant (> or =70% SigmaSTR and MB grade 2/3 or <70% SigmaSTR and MB grade 0/1) in 60.1% of patients and discordant in 39.9% of patients. The greatest survival was observed among patients with complete SigmaSTR (> or =70%) and MB grade 2/3 in whom the cumulative rates of death at 30 days and 1 year were 0.6 and 1.2%, respectively. Poorest survival was observed among patients with incomplete SigmaSTR (<70%) and reduced MB (grade 0/1), in whom 30 days and 1 year rates of death were 8.3 and 10.1%, respectively. Intermediate outcomes were present in patients with discordant MB and SigmaSTR. By multivariable analysis, however, SigmaSTR was an independent correlate of survival at 30 days and 1 year (P=0.05 and 0.01, respectively), whereas MB was no longer predictive (P=0.38 and 0.72, respectively). SigmaSTR and MB are not infrequently discordant after primary PCI. By univariate analysis, both measures of reperfusion success strongly correlate with survival and assessment of both yields incremental prognostic information beyond either measure alone. By multivariable analysis, however, SigmaSTR is the stronger prognostic variable.
AbstractList	ST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute myocardial infarction (AMI). We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI) in AMI has greater prognostic utility than either measure alone.AIMSST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute myocardial infarction (AMI). We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI) in AMI has greater prognostic utility than either measure alone.The 30 days and 1 year clinical outcomes of 456 patients were assessed as a function of SigmaSTR and MB after primary PCI from the CADILLAC trial. SigmaSTR and MB were concordant (> or =70% SigmaSTR and MB grade 2/3 or <70% SigmaSTR and MB grade 0/1) in 60.1% of patients and discordant in 39.9% of patients. The greatest survival was observed among patients with complete SigmaSTR (> or =70%) and MB grade 2/3 in whom the cumulative rates of death at 30 days and 1 year were 0.6 and 1.2%, respectively. Poorest survival was observed among patients with incomplete SigmaSTR (<70%) and reduced MB (grade 0/1), in whom 30 days and 1 year rates of death were 8.3 and 10.1%, respectively. Intermediate outcomes were present in patients with discordant MB and SigmaSTR. By multivariable analysis, however, SigmaSTR was an independent correlate of survival at 30 days and 1 year (P=0.05 and 0.01, respectively), whereas MB was no longer predictive (P=0.38 and 0.72, respectively).METHODS AND RESULTSThe 30 days and 1 year clinical outcomes of 456 patients were assessed as a function of SigmaSTR and MB after primary PCI from the CADILLAC trial. SigmaSTR and MB were concordant (> or =70% SigmaSTR and MB grade 2/3 or <70% SigmaSTR and MB grade 0/1) in 60.1% of patients and discordant in 39.9% of patients. The greatest survival was observed among patients with complete SigmaSTR (> or =70%) and MB grade 2/3 in whom the cumulative rates of death at 30 days and 1 year were 0.6 and 1.2%, respectively. Poorest survival was observed among patients with incomplete SigmaSTR (<70%) and reduced MB (grade 0/1), in whom 30 days and 1 year rates of death were 8.3 and 10.1%, respectively. Intermediate outcomes were present in patients with discordant MB and SigmaSTR. By multivariable analysis, however, SigmaSTR was an independent correlate of survival at 30 days and 1 year (P=0.05 and 0.01, respectively), whereas MB was no longer predictive (P=0.38 and 0.72, respectively).SigmaSTR and MB are not infrequently discordant after primary PCI. By univariate analysis, both measures of reperfusion success strongly correlate with survival and assessment of both yields incremental prognostic information beyond either measure alone. By multivariable analysis, however, SigmaSTR is the stronger prognostic variable.CONCLUSIONSigmaSTR and MB are not infrequently discordant after primary PCI. By univariate analysis, both measures of reperfusion success strongly correlate with survival and assessment of both yields incremental prognostic information beyond either measure alone. By multivariable analysis, however, SigmaSTR is the stronger prognostic variable. ST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute myocardial infarction (AMI). We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI) in AMI has greater prognostic utility than either measure alone. The 30 days and 1 year clinical outcomes of 456 patients were assessed as a function of SigmaSTR and MB after primary PCI from the CADILLAC trial. SigmaSTR and MB were concordant (> or =70% SigmaSTR and MB grade 2/3 or <70% SigmaSTR and MB grade 0/1) in 60.1% of patients and discordant in 39.9% of patients. The greatest survival was observed among patients with complete SigmaSTR (> or =70%) and MB grade 2/3 in whom the cumulative rates of death at 30 days and 1 year were 0.6 and 1.2%, respectively. Poorest survival was observed among patients with incomplete SigmaSTR (<70%) and reduced MB (grade 0/1), in whom 30 days and 1 year rates of death were 8.3 and 10.1%, respectively. Intermediate outcomes were present in patients with discordant MB and SigmaSTR. By multivariable analysis, however, SigmaSTR was an independent correlate of survival at 30 days and 1 year (P=0.05 and 0.01, respectively), whereas MB was no longer predictive (P=0.38 and 0.72, respectively). SigmaSTR and MB are not infrequently discordant after primary PCI. By univariate analysis, both measures of reperfusion success strongly correlate with survival and assessment of both yields incremental prognostic information beyond either measure alone. By multivariable analysis, however, SigmaSTR is the stronger prognostic variable.
Author	Tcheng, James E Zimetbaum, Peter Sorajja, Paul Costantini, Costantino Kandzari, David E Grines, Cindy L Cox, David A Stone, Gregg W Gersh, Bernard J Lansky, Alexandra J McLaughlin, Michael G Garcia, Eulogio Mehran, Roxana
Author_xml	– sequence: 1 givenname: Paul surname: Sorajja fullname: Sorajja, Paul organization: The Mayo Clinic and Mayo Foundation, Rochester, MN, USA – sequence: 2 givenname: Bernard J surname: Gersh fullname: Gersh, Bernard J – sequence: 3 givenname: Costantino surname: Costantini fullname: Costantini, Costantino – sequence: 4 givenname: Michael G surname: McLaughlin fullname: McLaughlin, Michael G – sequence: 5 givenname: Peter surname: Zimetbaum fullname: Zimetbaum, Peter – sequence: 6 givenname: David A surname: Cox fullname: Cox, David A – sequence: 7 givenname: Eulogio surname: Garcia fullname: Garcia, Eulogio – sequence: 8 givenname: James E surname: Tcheng fullname: Tcheng, James E – sequence: 9 givenname: Roxana surname: Mehran fullname: Mehran, Roxana – sequence: 10 givenname: Alexandra J surname: Lansky fullname: Lansky, Alexandra J – sequence: 11 givenname: David E surname: Kandzari fullname: Kandzari, David E – sequence: 12 givenname: Cindy L surname: Grines fullname: Grines, Cindy L – sequence: 13 givenname: Gregg W surname: Stone fullname: Stone, Gregg W
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/15734768$$D View this record in MEDLINE/PubMed
BookMark	eNpNkD1PwzAQhj0U0Q_YmZAntlA7cRxnRBVfUiUGisRW2c65dZXYxXaQ-kv4u6RqkZhOd_fo0b03RSPnHSB0Q8k9JXUxhz5sQYa0m8PWUl6N0ITQusw4F59jNI1xRwgRnPJLNKZlVbCKiwn6WfhOWQcN3ge_cT4mq3GfbGvTAXuD31dZhE0HLuEA2n9DOGDpGtwdvJahsbLFqu3jFkuTIAwS28kB2UPQfZIOfB-x9sG749S6gfkeXNa7ocFyYOC_yjojgz6ur9CFkW2E63OdoY-nx9XiJVu-Pb8uHpaZLvMqZQUVptA1JQC8VsJQw3itQQnGTNGUJauoboSSTU0KUmpVc8MYkEJRAYY0Jp-hu5N3iP_VQ0zrzkYNbXu6fc2rMhdM5AN4ewZ71UGzPidd_70y_wUvI33E
CitedBy_id	crossref_primary_10_1016_j_ahj_2005_11_010 crossref_primary_10_1002_ccd_21583 crossref_primary_10_1016_j_jacc_2009_12_054 crossref_primary_10_1097_MCA_0000000000000477 crossref_primary_10_4103_jicc_jicc_31_23 crossref_primary_10_1080_14017430600628144 crossref_primary_10_1111_j_1540_8183_2012_00768_x crossref_primary_10_1016_j_jcin_2013_03_013 crossref_primary_10_1016_S1885_5857_07_60010_3 crossref_primary_10_1093_ehjcr_ytae456 crossref_primary_10_1093_eurheartj_ehs246 crossref_primary_10_1177_00033197221098277 crossref_primary_10_1002_jcla_22598 crossref_primary_10_1016_j_carrev_2019_05_027 crossref_primary_10_1093_eurheartj_ehi217 crossref_primary_10_1177_2047487314533084 crossref_primary_10_1097_JIM_0000000000000096 crossref_primary_10_1007_s40256_019_00368_y crossref_primary_10_1016_j_ijcard_2012_12_049 crossref_primary_10_1161_CIRCULATIONAHA_112_093245 crossref_primary_10_1161_JAHA_118_009828 crossref_primary_10_1136_heartjnl_2024_324078 crossref_primary_10_1136_bmjopen_2018_025628 crossref_primary_10_1016_S2214_1235_15_30183_6 crossref_primary_10_1097_MAJ_0000000000000471 crossref_primary_10_1002_ccd_25563 crossref_primary_10_1016_j_ijcard_2011_07_078 crossref_primary_10_1007_s12265_013_9509_5 crossref_primary_10_1016_j_ahj_2011_04_014 crossref_primary_10_1038_s41598_023_32222_2 crossref_primary_10_1016_j_jacc_2007_09_051 crossref_primary_10_1093_eurheartj_ehn416 crossref_primary_10_3390_diagnostics12040932 crossref_primary_10_1016_j_ijcard_2016_03_184 crossref_primary_10_1016_j_jelectrocard_2024_153769 crossref_primary_10_1177_0003319716659193 crossref_primary_10_1016_j_yjmcc_2011_06_009 crossref_primary_10_1016_j_ehj_2013_04_002 crossref_primary_10_1093_eurheartj_eht351 crossref_primary_10_1016_j_amjcard_2018_03_353 crossref_primary_10_1161_CIRCINTERVENTIONS_116_004373 crossref_primary_10_1016_j_mehy_2017_03_010 crossref_primary_10_1016_j_ijcard_2016_09_011 crossref_primary_10_1136_openhrt_2021_001709 crossref_primary_10_1016_j_repce_2017_01_007 crossref_primary_10_1007_s00392_009_0756_z crossref_primary_10_1016_j_jacc_2007_11_066 crossref_primary_10_1016_j_jelectrocard_2012_06_028 crossref_primary_10_1111_joic_12133 crossref_primary_10_1016_j_carrev_2014_12_004 crossref_primary_10_1093_eurheartj_ehv484 crossref_primary_10_2459_JCM_0000000000000178 crossref_primary_10_1016_j_jcin_2013_02_009 crossref_primary_10_1002_ccd_22473 crossref_primary_10_1016_j_jacc_2009_03_054 crossref_primary_10_1016_j_jcin_2015_08_031 crossref_primary_10_1097_MD_0000000000035687 crossref_primary_10_1159_000371793 crossref_primary_10_1016_j_ahj_2010_02_031 crossref_primary_10_1097_MCA_0b013e328010a4b2 crossref_primary_10_1007_s10554_014_0430_z crossref_primary_10_1586_erc_11_49 crossref_primary_10_1016_j_ihj_2021_07_008 crossref_primary_10_1155_2013_364247 crossref_primary_10_1016_j_amjcard_2011_07_040 crossref_primary_10_1097_MCA_0000000000000661 crossref_primary_10_1016_j_carrev_2016_08_013 crossref_primary_10_1016_j_amjcard_2013_04_056 crossref_primary_10_2459_JCM_0b013e328356a2be crossref_primary_10_1161_CIRCOUTCOMES_109_923797 crossref_primary_10_1177_1076029613519851 crossref_primary_10_1186_s12872_020_01717_5 crossref_primary_10_1097_MCA_0000000000000458 crossref_primary_10_1007_s10557_019_06901_0 crossref_primary_10_1016_j_amjcard_2009_10_017 crossref_primary_10_1016_S0140_6736_14_60107_0 crossref_primary_10_1093_eurheartj_ehi606 crossref_primary_10_1097_MCA_0000000000000213 crossref_primary_10_1016_j_ihj_2016_04_006 crossref_primary_10_2459_JCM_0000000000000528 crossref_primary_10_2310_JIM_0b013e31826d9043 crossref_primary_10_1161_CIRCINTERVENTIONS_123_013675 crossref_primary_10_1111_j_1542_474X_2010_00350_x crossref_primary_10_1093_eurheartj_ehs065 crossref_primary_10_1016_j_ahj_2007_12_003 crossref_primary_10_1016_j_ahj_2013_07_025 crossref_primary_10_12688_f1000research_156104_1 crossref_primary_10_3390_jcm12175592 crossref_primary_10_1016_j_amjcard_2010_07_014 crossref_primary_10_1016_j_amjcard_2007_01_045 crossref_primary_10_1016_j_jacc_2008_04_006 crossref_primary_10_1016_j_jacc_2007_01_057 crossref_primary_10_1016_j_amjcard_2006_06_025 crossref_primary_10_1016_j_ijcard_2011_09_035 crossref_primary_10_1016_j_ahj_2010_08_009 crossref_primary_10_1016_j_repc_2017_01_006 crossref_primary_10_1016_j_tips_2015_06_004 crossref_primary_10_1093_eurheartj_ehs215 crossref_primary_10_1016_j_jcin_2010_08_024 crossref_primary_10_1111_ggi_12545 crossref_primary_10_1016_j_jcmg_2009_06_008 crossref_primary_10_1177_0300060520967856 crossref_primary_10_1016_j_ahj_2007_04_034 crossref_primary_10_18621_eurj_560531 crossref_primary_10_1007_s00392_015_0846_z crossref_primary_10_1016_j_jelectrocard_2008_08_038 crossref_primary_10_1136_hrt_2005_074716
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/eurheartj/ehi167
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
ExternalDocumentID	15734768
Genre	Clinical Trial Randomized Controlled Trial Journal Article
GroupedDBID	--- --K -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1B1 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6.Y 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNGD ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABQTQ ABSAR ABSMQ ABVGC ABWST ABXVV ABZBJ ACFRR ACGFO ACGFS ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEHUL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFIYH AFOFC AFSHK AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVWKF AXUDD AZFZN BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C1A C45 CAG CDBKE CGR COF CS3 CUY CVF CZ4 DAKXR DIK DILTD D~K E3Z EBS ECM EE~ EIF EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IHE IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 M49 MBLQV MHKGH ML0 N4W N9A NGC NOMLY NOYVH NPM NQ- NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OB3 OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RPZ RUSNO RW1 RXO RZF SEL TCURE TEORI TJX TMA UHS VH1 W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ~91 7X8 AAFWJ ABPQP ACUKT ADGHP ADNBA AEMQT AGQPQ AJBYB AJNCP ALXQX JXSIZ
ID	FETCH-LOGICAL-c527t-318f3c910ee69b8f1f469ceb844f3d55471cd8bad90305cb96f44e03b18ef0df2
IEDL.DBID	7X8
ISICitedReferencesCount	138
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000228892900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0195-668X
IngestDate	Sat Sep 27 18:18:46 EDT 2025 Wed Feb 19 01:44:42 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c527t-318f3c910ee69b8f1f469ceb844f3d55471cd8bad90305cb96f44e03b18ef0df2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://academic.oup.com/eurheartj/article-pdf/26/7/667/6124021/ehi167.pdf
PMID	15734768
PQID	67528482
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_67528482 pubmed_primary_15734768
PublicationCentury	2000
PublicationDate	2005-04-01
PublicationDateYYYYMMDD	2005-04-01
PublicationDate_xml	– month: 04 year: 2005 text: 2005-04-01 day: 01
PublicationDecade	2000
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	European heart journal
PublicationTitleAlternate	Eur Heart J
PublicationYear	2005
References	15757956 - Eur Heart J. 2005 Apr;26(7):634-6
References_xml	– reference: 15757956 - Eur Heart J. 2005 Apr;26(7):634-6
SSID	ssj0008616
Score	2.238831
Snippet	ST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	667
SubjectTerms	Aged Angioplasty, Balloon, Coronary - methods Coronary Circulation - physiology Electrocardiography Female Humans Male Microcirculation - physiology Middle Aged Multivariate Analysis Myocardial Infarction - physiopathology Myocardial Infarction - therapy Myocardial Reperfusion - methods Prognosis Recurrence Survival Analysis Treatment Outcome
Title	Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction
URI	https://www.ncbi.nlm.nih.gov/pubmed/15734768 https://www.proquest.com/docview/67528482
Volume	26
WOSCitedRecordID	wos000228892900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7Tifji_TKvefC1bG3TNgVBRBy-bAycsLfRJCc6me3cRdgv8e96TtbhHgQffCmkN5r0y8l3kpPzMXbtCxNERisvphAqoWXoZXEIWET2rgVAFCknNpG027LXSzsVdrPcC0NhlUub6Ay1KTTNkdeR2KIllcHt6MMjzShaWy0FNNZYNUQiQ5hOej-5wmXshE-dGmEcy165SIkufB1mY9KLnr7V4XXgLzTmf6eXbphp7vzvA3fZdkkv-d0CD3usAvk-22yVC-gH7Av7P_rCYDgFZuUFZWnmiD0i47yw_KnrTeCFZgw5ucqI8znPcsPf5zjmEZaGXA1nk1futMXxJS5XBR_BWM-QZkIxm3BNSRHo7GAlnhILPMN7YPVViG7sZ3T5kD03H7r3j16pzeDpKEimtOnahhq5BkCcKml9i362BiWFsKFBjpL42kiVmZQsilZpbIWARqh8CbZhbHDE1vMihxPGQ1DGoKOiG74R6JDKRoqmIUtNmqXaD5Iau1o2eB-xTwsai_r0l01eY8eLf9Yvq933oyQU6Emd_vnsGdty2VhdMM45q1rs9XDBNvTndDAZXzpI4bHdaX0DbKLc6g
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combined+prognostic+utility+of+ST-segment+recovery+and+myocardial+blush+after+primary+percutaneous+coronary+intervention+in+acute+myocardial+infarction&rft.jtitle=European+heart+journal&rft.au=Sorajja%2C+Paul&rft.au=Gersh%2C+Bernard+J&rft.au=Costantini%2C+Costantino&rft.au=McLaughlin%2C+Michael+G&rft.date=2005-04-01&rft.issn=0195-668X&rft.volume=26&rft.issue=7&rft.spage=667&rft_id=info:doi/10.1093%2Feurheartj%2Fehi167&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0195-668X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0195-668X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0195-668X&client=summon